Freestyle Libre 3 Plus Lands on Tandem t:slim X2

Tandem’s t:slim X2 insulin pump now works with Abbott’s FreeStyle Libre 3 Plus CGM, bringing real-time glucose data every minute to its Control-IQ+ system. This marks Libre 3 Plus’ fourth integration into a U.S.-based automated insulin delivery (AID) system—and it likely won’t be the last. Tandem also announced plans to integrate Abbott’s upcoming glucose-ketone sensor, a promising advancement for those at risk of diabetic ketoacidosis (DKA).

The Libre 3 Plus brings continuous glucose readings to the pump every minute, offering a 15-day wear time and a 60-minute warm-up. Data can be viewed on both the pump and the Tandem mobile app, giving users greater flexibility and real-time insight into their trends. With this integration, Abbott is quickly becoming a serious competitor to Dexcom, which is currently facing backlash over widespread G7 sensor failures, shortages, and growing concerns about transparency.

With this latest announcement, Abbott’s Libre 3 Plus is now supported by four AID systems in the U.S.: the Tandem t:slim X2, mylife Loop, twiist, and the iLet Bionic Pancreas. As more pump manufacturers bring the Libre 3 Plus into their ecosystems, Abbott’s sensor platform is clearly catching up in both capability and reach.

The t:slim X2 is powered by Tandem’s Control-IQ+ algorithm, which adjusts insulin every 5 minutes based on predicted glucose values. It’s the only FDA cleared system that allows users to set a Temp Basal while in automated insulin delivery mode. Alongside this new CGM integration, Tandem is also preparing to launch a new 7-day infusion set—designed to reduce site changes and improve comfort for users.

Looking ahead, it’s likely we’ll see Libre 3 Plus support on Tandem Mobi, Tandem’s smaller tubed pump, though no official timeline has been confirmed. For now, an early access program for the t:slim X2 integration has begun in the U.S., with wider rollout expected in the second half of 2025.

Stay updated on the latest diabetes tech and news by subscribing to our newsletter. If you’re finding value in our content, consider joining Diabetech All Access—our premium membership that unlocks exclusive content and supports our independent journalism.